Authors
Loading...
This commentary reveals how CXCL5 mediates immune suppression in PDAC, suggesting dual targeting may enhance immunotherapy outcomes.
Liang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: